Appendix 5

Core Outcome Measurement Set for Research and Clinical Practice in Post COVID-19 Condition (Long COVID) in Children and Young People: An International Delphi Consensus Study 'PC-COS Children'

Nina Seylanova MD^{*1}, Anastasia Chernyavskaya MD^{*2,3}, Natalia Degtyareva BSc⁴, Aigun Mursalova MD⁴, Ali Ajam BSc⁴, Lin Xiao BSc⁴, Khazhar Aktulaeva BSc⁴, Philipp Roshchin BSc⁴, Polina Bobkova MD⁴, Olalekan Lee Aiyegbusi PhD⁵, Anbarasu Theodore Anbu MD⁶, Christian Apfelbacher PhD⁷, Ali Akbar Asadi-Pooya MD^{8,9}, Liat Ashkenazi-Hoffnung MD¹⁰, Caroline Brackel MD^{11,12}, Danilo Buonsenso MD, PhD^{13,14}, Wouter de Groote¹⁵, Janet V. Diaz MD¹⁵, Daniele Dona MD, PhD¹⁶, Audrey Dunn Galvin PhD¹⁷, Jon Genuneit¹⁸, Helen Goss¹⁹, Sarah E. Hughes PhD²⁰, Christina J Jones PhD²¹, Krutika Kuppalli MD¹⁵, Laura A. Malone MD, PhD^{22,23}, Sammie McFarland¹⁹, Dale M. Needham, MD, PhD^{24,25,26}, Nikita Nekliudov MD, MSc²⁷, Timothy R Nicholson PhD²⁸, Carlos R. Oliveira MD, PhD^{29,30,31}, Nicoline Schiess³², Terry Y Segal MD³³, Louise Sigfrid³⁴, Claire Thorne PhD³⁵, Susanne Vijverberg PhD³⁶, John O. Warner³⁷, Wilson Milton Were¹⁵, Paula R. Williamson PhD³⁸, Daniel Munblit MD, PhD^{*39,40,41}, and the PC-COS Children Study Group^{**}

1 Independent researcher, London, UK

2 Department of Paediatrics and Paediatric Rheumatology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

3 National Medical Research Center for Children's Health, Moscow, Russia

4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

5 University of Birmingham, Birmingham, UK

6 Alder Hey Children's NHS Foundation Trust, Liverpool, UK

7 University of Magdeburg, Magdeburg, Germany

8 Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

9 Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, USA

10 Schneider Children's Medical Center of Israel, Petah Tikva, Israel

11 Amsterdam University Medical Centers, Amsterdam, the Netherlands

12 Department of Pediatrics, Tergooi Hospital, Blaricum, the Netherlands

13 Università Cattolica del Sacro Cuore, Rome, Italy

14 Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

15 World Health Organization, Switzerland

16 Department for Women's and Children's Health, University of Padua, Padua, Italy

17 University of Cork, Cork, Ireland

18 Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany

19 Long Covid Kids Charity, UK

20 Institute of Applied Health Research, University of Birmingham, Birmingham, UK

21 University of Surrey, Guildford, UK

22 Kennedy Krieger Institute, Baltimore, USA

23 Johns Hopkins University, Baltimore, USA

24 Outcomes After Critical Illness and Surgery (OACIS) Research Group, Johns Hopkins University, Baltimore, USA

25 Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA

26 Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, USA

27 Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA

28 King's College London, London, UK

29 Yale University School of Medicine, Department of Pediatrics, Section of Infectious Diseases, New Haven, USA

30 Yale University School of Public Health, Department of Biostatistics, Division of Health Informatics, New Haven, USA

31 Yale New Haven Children's Hospital, New Haven, USA

32 Brain Health Unit, Mental Health and Substance Use Department, World Health Organization, Switzerland

33 University College London Hospitals NHS Foundation Trust, London, UK

34 ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK

35 Population, Policy and Practice Research and Teaching Dept, University College London GOS Institute of Child Health, London, UK

36 Amsterdam University Medical Centers, Amsterdam, the Netherlands

37 Imperial College London, London, UK

38 Department of Health Data Science, University of Liverpool, Liverpool, UK

39 Division of Care in Long Term Conditions, Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK

40 Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

41 Research and Clinical Center for Neuropsychiatry, Moscow, Russia

*Authors contributed equally to the study: apart from the two joint first authors, who contributed equally, the primary study team members and the last author, authors are listed in alphabetical order.

** Listed at end of the manuscript

Corresponding author:

Daniel Munblit MD, PhD. Division of Care in Long Term Conditions, Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, United Kingdom

Email: daniel.munblit@kcl.ac.uk

1. First phase (COS development)

1.1. Study group and participants

The International Study Group, which represented the International Paediatric Post-COVID Condition in Children Collaboration (IP4C) and consisted of healthcare professionals, researchers, methodologists, WHO representatives, and affected CYP, played a crucial role in designing and executing the project. The "core group" consisting of DM, NS, AC, DB, CB and SV was responsible for the study's methodology and management. DM, TN, DMN, and PRW discussed methodology for design and conduct of the study following a similar process for an adult-based study ^{10,11}.

In the Delphi process, potential participants were selected from authors of published research, global institutions (e.g. WHO, IP4C, ISARIC), and patient organisations (e.g. Long Covid Kids). They received invitations to participate in the online Delphi process through direct emails from the research team or relevant patient/professional organisations. Additionally, Long COVID social media groups (primarily via Facebook and Twitter) were approached for recruitment, with eligibility criteria and contact information provided on the PC-COS study website (https://www.pc-cos.org/). Prospective participants underwent eligibility screening before registration as Delphi participants.

Only those participants who evaluated 50% or more of the outcomes in the first Delphi consensus round were invited to participate in the second round. Upon completion of both Delphi rounds, participants became eligible for the online consensus meeting and expressed interest in meeting participation as part of the online Delphi process. This approach aimed to ensure global representation and balanced stakeholder group distribution among attendees.

1.2. Delphi process and definitions

The order of outcomes presented in the Delphi process was randomised by domain categories ("mortality/survival", "physiological/clinical", "life impact" and "resource use"). A free-text option was available to suggest additional outcomes, which were assessed for inclusion in the second Delphi round (outcomes that formed $\geq 1\%$ of the total number of suggested outcomes were included). All outcomes from the first round were included in the second round, regardless of the results.

2. Second phase (Outcome measurement instruments consensus)

2.1. Literature review of outcome measurement instruments

Instruments were systematically mapped to the core outcomes defined in the first phase of the project. This process was also instrumental in identifying and removing any duplicates and ensuring accurate mapping to outcomes. Any instruments that did not map to any of the COS domains were excluded from consideration. Additional instruments not used in published research and clinical trial protocols were considered based on expert suggestions and experience of adult project 11. For instance, PROMIS instruments were screened for eligibility and added to the list.